Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHerance Camacho, José Raul
dc.contributor.authorVelasquez Arevalo, Mayra Alejandra
dc.contributor.authorGarcia León, Daniel
dc.contributor.authorAparicio Gomez, Carolina
dc.contributor.authorMarès Pagès, Roso
dc.contributor.authorSimó Servat, Olga
dc.contributor.authorCastell Conesa, Joan
dc.contributor.authorHernández Pascual, Cristina
dc.contributor.authorAguade Bruix, Santiago
dc.contributor.authorSimó Canonge, Rafael
dc.contributor.authorPaun, Bruno
dc.date.accessioned2022-12-12T11:03:04Z
dc.date.available2022-12-12T11:03:04Z
dc.date.issued2022-01-02
dc.identifier.citationHerance JR, Simó R, Velasquez MA, Paun B, García-Leon D, Aparicio C, et al. Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT. J Pers Med. 2022 Jan 2;12:30.
dc.identifier.issn2075-4426
dc.identifier.urihttps://hdl.handle.net/11351/8647
dc.descriptionCardiovascular risk; Myocardial insulin resistance; Type 2 diabetes
dc.description.abstractBackground: Systemic insulin resistance is generally postulated as an independent risk factor of cardiovascular events in type 2 diabetes (T2D). However, the role of myocardial insulin resistance (mIR) remains to be clarified. Methods: Two 18F-FDG PET/CT scans were performed on forty-three T2D patients at baseline and after hyperinsulinemic–euglycemic clamp (HEC). Myocardial insulin sensitivity (mIS) was determined by measuring the increment in myocardial 18F-FDG uptake after HEC. Coronary artery calcium scoring (CACs) and myocardial radiodensity (mRD) were assessed by CT. Results: After HEC, seventeen patients exhibited a strikingly enhancement of myocardial 18F-FDG uptake and twenty-six a marginal increase, thus revealing mIS and mIR, respectively. Patients with mIR showed higher mRD (HU: 38.95 [33.81–44.06] vs. 30.82 [21.48–38.02]; p = 0.03) and CACs > 400 (AU: 52% vs. 29%; p = 0.002) than patients with mIS. In addition, HOMA-IR and mIS only showed a correlation in those patients with mIR. Conclusions: 18F-FDG PET combined with HEC is a reliable method for identifying patients with mIR. This subgroup of patients was found to be specifically at high risk of developing cardiovascular events and showed myocardial structural changes. Moreover, the gold-standard HOMA-IR index was only associated with mIR in this subgroup of patients. Our results open up a new avenue for stratifying patients with cardiovascular risk in T2D.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesJournal of Personalized Medicine;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectDiabetis no-insulinodependent
dc.subjectInsulinoresistència
dc.subjectMiocardi - Malalties
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshInsulin Resistance
dc.subject.meshDiabetic Cardiomyopathies
dc.titlePhenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/jpm12010030
dc.subject.decsdiabetes mellitus tipo II
dc.subject.decsresistencia a la insulina
dc.subject.decsmiocardiopatías diabéticas
dc.relation.publishversionhttps://doi.org/10.3390/jpm12010030
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Herance JR] Grup de Recerca en Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERBBN, Instituto de Salud Carlos III, Madrid, Spain. [Simó R, Simó-Servat O, Hernández C] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain. [Velasquez MA] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Paun B, García-Leon D, Aparicio C, Marés R, Castell-Conesa J, Aguadé-Bruix S] Grup de Recerca en Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35055345
dc.identifier.wos000746238400001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F02064
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01588
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record